A Phase 1 First-in-Human Single-Ascending-Dose Trial With ESB1609, a Selective Agonist to the Sphingosine-1-Phosphate Receptor 5.
France NP, Rubino C, Safir MC, Maurer M, Duong T, Singamsetty D, Abd-Elaziz K, Chou T, Sankaranarayanan S, Ettema M, Cosford R, Dogterom P, Liu E, Barlow C.
France NP, et al. Among authors: cosford r.
Clin Pharmacol Drug Dev. 2023 Jun;12(6):625-638. doi: 10.1002/cpdd.1256. Epub 2023 May 16.
Clin Pharmacol Drug Dev. 2023.
PMID: 37191222
Clinical Trial.